Compare LKQ & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LKQ | SRRK |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.8B |
| IPO Year | 2003 | 2018 |
| Metric | LKQ | SRRK |
|---|---|---|
| Price | $24.51 | $52.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $42.33 | ★ $56.17 |
| AVG Volume (30 Days) | ★ 3.4M | 1.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $13,651,000,000.00 | N/A |
| Revenue This Year | $2.18 | N/A |
| Revenue Next Year | $1.71 | $534.24 |
| P/E Ratio | $29.60 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.17 | $27.07 |
| 52 Week High | $37.13 | $58.49 |
| Indicator | LKQ | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 46.90 | 54.97 |
| Support Level | $21.17 | $51.32 |
| Resistance Level | $27.18 | $58.49 |
| Average True Range (ATR) | 0.82 | 2.42 |
| MACD | 0.01 | 0.34 |
| Stochastic Oscillator | 54.66 | 80.00 |
LKQ Corp is a world-wide distributor of vehicle products, including replacement parts, components and systems used in the repair and maintenance of vehicles, and specialty aftermarket products and accessories to improve the performance, functionality and appearance of vehicles. The company is organized into three operating segments: North America; Europe; and Specialty segment. It derives maximum revenue from Europe Segment. Europe segment is a provider of alternative vehicle replacement and maintenance products in Germany, the United Kingdom, the Benelux region (Belgium, Netherlands, and Luxembourg), Italy, Czech Republic, Austria, Slovakia, France and various other European countries.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.